The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://sidneyblmb447160.ourabilitywiki.com/10473297/retatrutide_vs_tirzepatide_a_comparative_analysis